Analysts Have Lowered Expectations For Solteq Oyj After Its Latest Results

It's been a sad week for Solteq Oyj (HEL:SOLTEQ), who've watched their investment drop 10% to €1.30 in the week since the company reported its annual result. Results overall were respectable, with statutory earnings of €0.15 per share roughly in line with what analysts had forecast. Revenues of €61m came in 4.4% ahead of analyst predictions. Following the result, analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

Check out our latest analysis for Solteq Oyj

HLSE:SOLTEQ Past and Future Earnings, March 1st 2020
HLSE:SOLTEQ Past and Future Earnings, March 1st 2020

After the latest results, the consensus from Solteq Oyj's sole analyst is for revenues of €57.5m in 2020, which would reflect a measurable 5.6% decline in sales compared to the last year of performance. Statutory earnings per share are expected to plunge 60% to €0.06 in the same period. Before this earnings report, analysts had been forecasting revenues of €61.5m and earnings per share (EPS) of €0.13 in 2020. From this we can that analyst sentiment has definitely become more bearish after the latest results, leading to lower revenue forecasts and a pretty serious reduction to earnings per share estimates.

Despite the cuts to forecast earnings, there was no real change to the €1.43 price target, showing that analysts don't think the changes have a meaningful impact on the stock's intrinsic value.

In addition, we can look to Solteq Oyj's past performance and see whether business is expected to improve, and if the company is expected to perform better than wider market. We would highlight that sales are expected to reverse, with the forecast 5.6% revenue decline a notable change from historical growth of 4.1% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same market are forecast to see their revenue grow 13% annually for the foreseeable future. It's pretty clear that Solteq Oyj's revenues are expected to perform substantially worse than the wider market.

Advertisement

The Bottom Line

The biggest concern with the new estimates is that analysts have reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Solteq Oyj. Unfortunately, analysts also downgraded their revenue estimates, and our data indicates revenues are expected to perform worse than the wider market. Even so, earnings per share are more important to the intrinsic value of the business. The consensus price target held steady at €1.43, with the latest estimates not enough to have an impact on analysts' estimated valuations.

Even so, the longer term trajectory of the business is much more important for the value creation of shareholders. At least one analyst has provided forecasts out to 2022, which can be seen for free on our platform here.

It might also be worth considering whether Solteq Oyj's debt load is appropriate, using our debt analysis tools on the Simply Wall St platform, here.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

About HLSE:SOLTEQ

Solteq Oyj

An IT services and software solutions company, engages in the digitalization of business and industry-specific software in Finland, Sweden, Norway, Denmark, Poland, and the United Kingdom.

Undervalued with moderate growth potential.

Advertisement

Weekly Picks

CE
Ceazar
SPAI logo
Ceazar on Sparc AI ·

When GPS fails: this small cap is fixing a $54B drone problem

Fair Value:CA$5.2554.7% undervalued
110 users have followed this narrative
0 users have commented on this narrative
24 users have liked this narrative
BL
BlackGoat
IREN logo
BlackGoat on IREN ·

IREN's Bold Moves in Sustainable Bitcoin Mining & AI Data Centers

Fair Value:US$71.4859.0% undervalued
213 users have followed this narrative
8 users have commented on this narrative
32 users have liked this narrative
HE
HedgeY
ARM logo
HedgeY on Arm Holdings ·

The Architecture Layer of AI Computing - But Priced Like the Future Already Arrived?

Fair Value:US$43047.7% undervalued
20 users have followed this narrative
1 users have commented on this narrative
6 users have liked this narrative
HI
Hidden_Rock_Capital
FISV logo
Hidden_Rock_Capital on Fiserv ·

Temporary "perfect storm" leads to opportunity to buy financial services leader for less than 5x long-term earnings

Fair Value:US$119.9953.6% undervalued
25 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative

Updated Narratives

TH
TheGrayWolf_80
SCHD logo
TheGrayWolf_80 on Schwab Strategic Trust - Schwab U.S. Dividend Equity ETF ·

Building a 75/15/10 Income Machine with Schwab's Dividend ETF

Fair Value:US$63.7546.9% undervalued
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
SI
MSFT logo
simplydunno on Microsoft ·

Microsoft's Capex Bill Comes Due Before the AI Revenue Does

Fair Value:US$512.123.7% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
HE
NGXGROUP logo
Henrynuke03 on Nigerian Exchange Group ·

Future Growth Awaits NGXGROUP with New High-Profile Listings

Fair Value:₦221.1732.3% undervalued
7 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28032.1% undervalued
211 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.917.0% undervalued
97 users have followed this narrative
0 users have commented on this narrative
7 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6510.2% undervalued
74 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0